# The Peptide Evidence FAQ > Research Peptide FAQ — Research Peptide Fundamentals — Research Peptide Fundamentals research peptides FAQ: evidence-based answers on thymosin alpha-1, MOTS-c, BPC-157, and tirzepatide. **QUESTIONS / SOURCE-ANCHORED ANSWERS** Direct answers calibrated to study model, sample size, regulatory status, and what the supplied literature cannot establish. ## What is thymosin alpha 1? Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide; thymalfasin is its sequence-identical synthetic form [7]. It acts as an immunomodulator at the innate–adaptive immune interface rather than as a simple general immune stimulant. The peptide has been studied for decades and is used as a medicine in more than 35 countries, but it does not have US marketing approval [2]. ## What does thymosin alpha 1 do? Experimental work shows signaling through Toll-like receptors on dendritic cells and monocytes, supporting antigen presentation and T-cell responses. It can also activate an IDO-dependent regulatory pathway that increases interleukin-10 and regulatory T cells [6]. This dual pattern may support immune response while restraining excess inflammation. Clinical effect depends on the disease setting; the largest sepsis trial found no mortality benefit [1]. ## What is thymosin alpha 1 used for? The literature covers viral disease, sepsis, cancer-combination strategies, and immune reconstitution. An oncology review describes it as an immunomodulatory adjunct studied with chemotherapy and immunotherapy [4]. A retrospective severe COVID-19 cohort reported lower mortality and improved T-cell markers, but that design cannot establish causality [3]. In sepsis, the strongest phase 3 trial was negative [1]. The evidence does not support one universal use claim. ## Is thymosin alpha 1 FDA-approved? No. Thymosin alpha-1 is not FDA-approved for marketing in the United States. A comprehensive review describes thymalfasin as approved in more than 35 other countries [2]. International authorization and US approval are different regulatory facts, and neither validates the identity or sterility of material sold outside a regulated drug channel. ## What does the MOTS-c peptide do? MOTS-c is a mitochondrial-encoded stress signal. It is linked to AMPK-mediated energy sensing, can enter the nucleus under metabolic stress, and regulates antioxidant and metabolic genes [10][12]. Direct binding and activation of CK2 has also been demonstrated in experimental systems [8]. Mouse studies report better muscle function and exercise performance [11]. There is no human efficacy trial in this corpus, so those outcomes cannot be projected onto people. ## What are the negative side effects of MOTS-c? A reliable human adverse-effect rate cannot be stated because controlled human administration and safety trials are absent from the supplied record. The main negative finding is uncertainty: human pharmacokinetics, interactions, longer-term effects, and population differences are not defined. Reports from unverified research use would be anecdotal, not clinical evidence, and product identity adds a separate risk. ## Is MOTS-c legal to buy? MOTS-c is not an FDA-approved medicine. Legal questions depend on jurisdiction and transaction context, and this editorial digest does not provide sourcing guidance. Research-chemical availability is not the same as authorization for human use. Competitive athletes face an additional constraint because anti-doping authorities treat the peptide as prohibited. ## How often is MOTS-c injected? There is no evidence-based human injection schedule to report. No approved formulation or human efficacy dose exists in the supplied corpus, and animal exposures cannot be converted into human instructions. Alien Peptides does not provide dosing or administration advice. ## What does BPC-157 do in the body? That question is established mainly in experimental models, not in the human body. BPC-157 activates VEGFR2-related angiogenic signaling and promotes new-vessel formation in cell and animal systems [16]. Rat work reports reduced gastric ulcer area and faster tissue rebuilding [17]. A review found only three human pilots and no large rigorous trials [14], so human repair claims remain unproven. ## Is BPC-157 a growth hormone? No. BPC-157 is a synthetic 15-amino-acid gastric-derived peptide, not growth hormone. Some experimental work proposes interaction with growth-hormone-receptor signaling in tendon cells, but interacting with a pathway does not make two molecules the same. Its clearest supplied mechanism is VEGFR2-linked angiogenesis [16]. ## Does BPC-157 work immediately? No controlled human efficacy dataset supports an onset claim. Online timelines are anecdotal, not clinical evidence. The human record includes only a few pilots, and a 2025 review concludes that large rigorous trials are lacking [14]. Animal healing results establish hypotheses, not a reliable human timetable. ## Does BPC-157 damage the liver? The evidence is too limited to rule in or rule out uncommon human liver injury. In a two-person pilot, measured hepatic markers did not change [13]. That observation is reassuring only for those two participants and cannot establish population safety, delayed risk, or safety of unregulated products. ## What is tirzepatide and how does it work? Tirzepatide is an FDA-approved synthetic peptide medicine and dual agonist of the GIP and GLP-1 receptors [19]. It enhances glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite. Large randomized trials found substantial weight and glucose effects [18][21][22]. Gastrointestinal effects are common, and a pooled analysis found a significant increase in the combined gallbladder or biliary endpoint [20]. ## What is tirzepatide used for? It is an FDA-approved prescription medicine for defined metabolic indications, including type 2 diabetes, with additional approved indications described by current labeling and clinical references [19]. The research record here includes randomized obesity and type 2 diabetes trials [18][21][22]. Approval does not turn a literature summary into personal medical guidance; eligibility, contraindications, and monitoring belong in clinical care. --- Alien Peptides is an independent audit of frontier peptide findings, not a clinic, vendor, prescription, or substitute for medical judgment.